Psilocybin could be an unexpected avenue for treating an injury that currently has few options beyond rest and symptom management.
Articles on Psilocybin
Displaying 1 - 20 of 53 articles
Brains scans show a signature linked to a dissolved separation between the self and the world.
The psychedelic treatment is moving through the FDA clinical trial process in Colorado and elsewhere.
The psychiatrist used to have to stay with the patient during their entire session. Now they’ll be able to leave the room after administering the drug.
Doctors working in palliative care see promise in emerging therapies involving psychedelic drugs, but say many questions still need to be addressed.
A woman with advanced dementia appeared to regain speech and independence after psilocybin. The findings are intriguing, but far from proof.
Our trial found psilocybin worked fast and lasted months, but unpicking the drug’s true effect from patients’ expectations remains a challenge.
Psilocybin falls into a regulatory gray zone, with strict limitations around how it can be studied. As a result, very little is known about its health risks, despite its surging popularity.
Hallucinogenic chocolate bars were removed from six Denver-area gas stations.
Psychedelic therapy often promises transcendent mystical experiences. But research suggests context and expectation may matter more than the trip itself.
Psychedelic medicine is surging back into favour in 2025, but the very features that make these drugs promising may be the hardest to commercialise.
Studies show psilocybin therapy can rapidly reduce anxiety and depression in terminally ill patients, but UK regulations make access nearly impossible.
The discovery could also make the production of psilocybin in the lab more sustainable.
The magic mushroom longevity study that’s too good to be true.
Psychedelic-assisted therapy offers promise. But new research highlights concerns about safety and accessibility.
Psychedelics are marketed as a way for the general population to extract more work out of their already overworked lives, and to be happy about it in the process.
MDMA, psilocybin, ketamine derivatives, and other hallucinogens are authorised in certain countries to treat depression or post-traumatic stress disorder. What is the level of evidence?
Psilocybin studies to treat mental health disorders have tended to only look at short-term results.
Pharmaceutical giants like Johnson & Johnson as well as smaller startups are investing in psychedelic drug development, and both are pursuing FDA approval for their patented psilocybin formulations.
Researchers in American scanned the ‘hell out of’ participants brains while they tripped on mushrooms.
Top contributors
-
Senior Lecturer of Addiction, Edith Cowan University
-
Professor and Canada Research Chair in the History of Health & Social Justice, University of Saskatchewan
-
Distinguished Professor of Pharmacy Practice, University of Connecticut
-
Adjunct Professor, Psychiatry, Karolinska Institutet
-
PhD student in Clinical Psychology, York University, Canada
-
Research Scientist, Queen's Health Sciences and Assistant Professor, Department of Psychiatry, Queen's University, Ontario
-
PhD Candidate, Congnitive Neuroscience, University of Toronto
-
Research fellow, Swinburne University of Technology
-
Killam Postdoctoral Research Fellow, Dalhousie University; Queen's University, Ontario
-
Associate Professor, Cognitive Psychology, Leiden University
-
Medicinal Chemist, UNSW
-
Associate Lecturer, School of Psychology, University of Wollongong
-
Adjunct Professor in the School of Child & Youth Care, University of Victoria
-
Professor, Monash University
-
Director Clinical Trials and Professor Cognitive Neuropsychiatry Centre for Mental Health and Brain Sciences, Swinburne University of Technology